Trial Profile

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DB 1310 (Primary) ; Trastuzumab
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Head and neck cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Duality Biologics

05 Jun 2025 Results presented in a Duality Biologics media release.
05 Jun 2025 According to Duality Biologics media release, data from this study were Presented Orally at the 2025 ASCO Annual Meeting.
07 Mar 2025 Protocol has been amended , number of arms changed from 22 to 24.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com